[go: up one dir, main page]

MA27145A1 - Methodes pour le traitement de maladies neovasculaires oculaires - Google Patents

Methodes pour le traitement de maladies neovasculaires oculaires

Info

Publication number
MA27145A1
MA27145A1 MA27662A MA27662A MA27145A1 MA 27145 A1 MA27145 A1 MA 27145A1 MA 27662 A MA27662 A MA 27662A MA 27662 A MA27662 A MA 27662A MA 27145 A1 MA27145 A1 MA 27145A1
Authority
MA
Morocco
Prior art keywords
treatment
methods
therapy
eye diseases
neovascular eye
Prior art date
Application number
MA27662A
Other languages
English (en)
Inventor
David R Guyer
Original Assignee
Eyetech Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyetech Pharmaceuticals filed Critical Eyetech Pharmaceuticals
Publication of MA27145A1 publication Critical patent/MA27145A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite : EYETECH PHARMACEUTICALS REVENDICATION DE PRIORITES US 9 Novembre 2001 60/332,304 Voir en annexe le titre de l'invention et le texte de l'abrégé Méthodes pour le traitement de maladies néovasculaires oculaires Il est décrit dans le présent mémoire des méthodes pour le traitement d'une maladie néovasculaire oculaire en utilisant une thérapie anti-VEGF en association avec une seconde thérapie qui inhibe le développement d'une néovascularisation oculaire ou qui détruit des vaisseaux sanguins anormaux dans l'„il, telle qu'une thérapie photodynamique.
MA27662A 2001-11-09 2004-04-29 Methodes pour le traitement de maladies neovasculaires oculaires MA27145A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33230401P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
MA27145A1 true MA27145A1 (fr) 2005-01-03

Family

ID=23297643

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27662A MA27145A1 (fr) 2001-11-09 2004-04-29 Methodes pour le traitement de maladies neovasculaires oculaires

Country Status (26)

Country Link
US (3) US20030171320A1 (fr)
EP (1) EP1441743A4 (fr)
JP (1) JP2005511576A (fr)
KR (1) KR20050044372A (fr)
CN (1) CN1582156A (fr)
AP (1) AP1750A (fr)
AR (1) AR037307A1 (fr)
BR (1) BR0213975A (fr)
CA (1) CA2464007A1 (fr)
CR (1) CR7330A (fr)
EA (1) EA006746B1 (fr)
EC (1) ECSP045098A (fr)
GE (1) GEP20063755B (fr)
HR (1) HRP20040406A2 (fr)
IL (1) IL161327A0 (fr)
IS (1) IS7215A (fr)
MA (1) MA27145A1 (fr)
MX (1) MXPA04004363A (fr)
NO (1) NO20041882L (fr)
OA (1) OA12720A (fr)
PL (1) PL371929A1 (fr)
RS (1) RS35404A (fr)
TN (1) TNSN04081A1 (fr)
TW (1) TWI260327B (fr)
WO (1) WO2003039404A2 (fr)
ZA (1) ZA200402753B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398901C (fr) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methodes et compositions destinees au traitement d'affections oculaires
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
WO2004080284A2 (fr) * 2003-03-07 2004-09-23 Board Of Regents, The University Of Texas System Therapie photodynamique ciblee sur les anticorps
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
KR101501870B1 (ko) * 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
CN1882338A (zh) 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
US7575321B2 (en) * 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
DK1682537T3 (da) 2003-11-05 2012-07-09 Sarcode Bioscience Inc Modulatorer af celleadhæsion
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
EP1732571A4 (fr) * 2004-03-05 2009-09-09 Archemix Corp Modulation controlee de la pharmacocinetique et la repartition biologique de la therapeutique a base d'aptameres
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
JP4943324B2 (ja) * 2004-06-04 2012-05-30 ザ スクリプス リサーチ インスティチュート 新生血管病の治療のための組成物および方法
JP2008507284A (ja) * 2004-07-23 2008-03-13 （オーエスアイ）アイテツク・インコーポレーテツド デュアルハイブリダイゼーションによるオリゴヌクレオチドの検出
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
NZ596663A (en) * 2004-10-21 2013-07-26 Genentech Inc Use of vegf antagonists in intraocular neovascular disease treatment
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006047716A2 (fr) * 2004-10-26 2006-05-04 Bioresponse Llc Utilisation d'indoles lies au diindolylmethane et d'inhibiteurs du recepteur de facteur de croissance pour le traitement d'une maladie associee au cytomegalovirus humain
US20060110429A1 (en) * 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
HUE027352T2 (en) 2005-02-09 2016-09-28 Santen Pharmaceutical Co Ltd Liquid formulations for the treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070121754A (ko) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 질환 또는 상태의 치료를 위한 약물 송달 시스템
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
US20090281184A1 (en) * 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP1981520A2 (fr) * 2006-01-30 2008-10-22 (OSI) Eyetech, Inc. Polytherapie destinee au traitement de troubles neovasculaires
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
HUE018715T2 (hu) * 2006-06-16 2024-10-28 Regeneron Pharma Intravitreális beadásra alkalmas VEGF antagonista készítmények
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
WO2008103320A1 (fr) * 2007-02-16 2008-08-28 Novacea, Inc. Méthodes de traitement de troubles ophtalmiques utilisant des anthraquinones
ES2374336T3 (es) * 2007-05-11 2012-02-15 Santen Pharmaceutical Co., Ltd Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo.
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CA2958665C (fr) * 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions et procedes pour le traitement de la retinopathie diabetique
WO2010045506A2 (fr) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Système d'administration prolongée de médicament
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
US9226917B2 (en) 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
JP2012517434A (ja) * 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
WO2011009020A2 (fr) 2009-07-16 2011-01-20 Mallinckrodt Inc. Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
BR112012017071A2 (pt) * 2010-01-14 2016-04-12 Univ Nagoya City produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
EP2663325A1 (fr) 2011-01-13 2013-11-20 Regeneron Pharmaceuticals, Inc. Utilisation d'antagoniste de vegf pour traiter des troubles oculaires angiogéniques
JPWO2012105610A1 (ja) 2011-02-02 2014-07-03 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
KR101303920B1 (ko) * 2011-04-26 2013-09-05 서울대학교산학협력단 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
CN103721257B (zh) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
RU2527360C1 (ru) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ комбинированного лечения ретиноваскулярного макулярного отека
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
US10183989B2 (en) * 2013-12-24 2019-01-22 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3359555B1 (fr) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Régimes posologiques
CA3179836A1 (fr) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Utilisation de l'inhibiteur de vegf pour traiter la degenerescence maculaire dans une population de patients
NZ783685A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
DE102017008721A1 (de) 2017-09-16 2019-03-21 protectismundi GmbH Verfahren und Vorrichtung zur Hochhausbrandbekämfpung
SG11202004268PA (en) 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
KR20200123091A (ko) 2017-12-15 2020-10-28 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
WO2019210097A1 (fr) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113101530B (zh) * 2021-04-14 2022-09-30 中国人民解放军陆军特色医学中心 一种通过无线充电激活玻璃体腔植入性发光二极管的系统
KR20240121668A (ko) 2023-02-01 2024-08-09 아주대학교산학협력단 염증성 눈질환의 예방 및 치료용 조성물
WO2024243081A1 (fr) * 2023-05-19 2024-11-28 The Trustees Of Columbia University In The City Of New York Traitement d'une pression intraoculaire élevée avec du nicotinamide
CN118108804B (zh) * 2024-04-26 2024-06-25 山东大学 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
AU6813694A (en) * 1994-03-14 1995-10-03 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
JP3845469B2 (ja) * 1996-02-21 2006-11-15 明治製菓株式会社 眼底の新生血管の閉塞に用いる投与剤
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
CA2269072C (fr) * 1996-10-25 2006-02-14 Nexstar Pharmaceuticals, Inc. Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
WO2001051087A2 (fr) * 2000-01-12 2001-07-19 Light Sciences Corporation Nouveau traitement pour maladie des yeux
CA2398901C (fr) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methodes et compositions destinees au traitement d'affections oculaires
WO2001068053A2 (fr) * 2000-03-10 2001-09-20 Insite Vision Incorporated Procedes et compositions pour traiter et prevenir des affections ophtalmiques de la partie posterieure de l'oeil
RU2271222C2 (ru) * 2000-03-24 2006-03-10 Новартис Аг Улучшенный способ лечения неоваскуляризации
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US20060258629A1 (en) * 2002-10-18 2006-11-16 Freeman William R Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
JP2005511576A (ja) 2005-04-28
BR0213975A (pt) 2005-05-10
KR20050044372A (ko) 2005-05-12
CR7330A (es) 2005-06-15
HRP20040406A2 (en) 2005-02-28
TW200302226A (en) 2003-08-01
EP1441743A4 (fr) 2009-02-25
CA2464007A1 (fr) 2003-05-15
IS7215A (is) 2004-04-07
WO2003039404A3 (fr) 2004-02-12
NO20041882L (no) 2004-05-07
US20040167091A1 (en) 2004-08-26
US20070027101A1 (en) 2007-02-01
AR037307A1 (es) 2004-11-03
CN1582156A (zh) 2005-02-16
TNSN04081A1 (fr) 2006-06-01
OA12720A (en) 2006-06-27
EP1441743A2 (fr) 2004-08-04
PL371929A1 (en) 2005-07-11
ECSP045098A (es) 2004-07-23
US20030171320A1 (en) 2003-09-11
IL161327A0 (en) 2004-09-27
EA200400518A1 (ru) 2004-12-30
TWI260327B (en) 2006-08-21
WO2003039404A2 (fr) 2003-05-15
AP1750A (en) 2007-06-23
GEP20063755B (en) 2006-02-27
EA006746B1 (ru) 2006-04-28
MXPA04004363A (es) 2005-05-16
ZA200402753B (en) 2005-01-05
RS35404A (sr) 2006-10-27
AP2004003026A0 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
MA27145A1 (fr) Methodes pour le traitement de maladies neovasculaires oculaires
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
WO2004026246A3 (fr) Procedes pour traiter les alterations de la memoire liees a l'age (aami), les deficits cognitifs legers (mci) et les demences au moyen d'inhibiteurs du cycle cellulaire
EP1765362A4 (fr) Compositions et méthodes pour le traitement de maladies néovasculaires
NO20071512L (no) Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor.
Meltzer Suicide in Schizophrenia.
MA27060A1 (fr) Therapeutique mixte pour le traitement du cancer
WO2002062385A3 (fr) Methode de prevention de la perte de la vue
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2003049717A3 (fr) Transport de proteines mal pliees par la voie secretoire et methodes de traitement de maladies associees
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
EP1666064A4 (fr) Medicament destine a traiter des maladies associees a une translocation d'un gene d'immunoglobuline
WO2005061002A3 (fr) Composition et procedes pour la modulation de l'activite du systeme nerveux central
WO2003092701A3 (fr) Utilisation d'acides amino-alcane-phosphoniques substitués
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
ATE300947T1 (de) Behandlung von erkrankungen mit zystenbildung
AU2002351908A8 (en) Treatment of neovascular ophthalmic disease
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
Kumar et al. Tacrolimus-induced mania in a patient with nephrotic syndrome
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo